• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Manuso James S J claimed no ownership of stock in the company (SEC Form 3)

    10/22/24 8:33:41 PM ET
    $KTRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KTRA alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    MANUSO JAMES S J

    (Last) (First) (Middle)
    10500 UNIVERSITY CENTER DRIVE, SUITE 110

    (Street)
    TAMPA FL 33612

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    10/18/2024
    3. Issuer Name and Ticker or Trading Symbol
    Kintara Therapeutics, Inc. [ KTRA ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 0(1) D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. This Form 3 is being filed solely to reflect the reporting person becoming a director, officer or 10% owner of TuHURA Biosciences, Inc.
    Remarks:
    See Exhibit 24 - Power of Attorney.
    /s/ Dan Dearborn as Power of Attorney for James Manuso 10/22/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KTRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KTRA

    DatePrice TargetRatingAnalyst
    1/20/2022$6.00 → $3.00Buy
    HC Wainwright & Co.
    9/30/2021$7.00 → $5.00Buy
    Aegis Capital
    9/28/2021$6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $KTRA
    SEC Filings

    See more
    • Kintara Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Leadership Update, Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Material Modification to Rights of Security Holders, Changes in Control of Registrant

      8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)

      10/21/24 8:30:25 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Kintara Therapeutics Inc.

      EFFECT - Kintara Therapeutics, Inc. (0001498382) (Filer)

      10/16/24 12:15:03 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kintara Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)

      10/15/24 4:20:08 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Scientific Officer Yamashita Dennis

      4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 9:12:33 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Patel Vijay claimed ownership of 7,999,557 shares (SEC Form 3)

      3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 8:50:14 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Ng George K

      4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)

      10/22/24 8:47:13 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024

      SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 16, 2024. Kintara announced today that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 18, 2024, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger

      10/16/24 12:54:00 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences

      SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 17, 2024, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger (the "Merger") with TuHURA Biosciences, Inc. ("TuHURA"), with a new CUSIP number 898920 103.

      10/16/24 11:58:00 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kintara Therapeutics Announces Correction to Prior Announcement Regarding CVR Issuance in Connection with the Proposed Merger with TuHURA Biosciences Expected to Close on October 18, 2024

      SAN DIEGO, Oct. 15, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 14, 2024, regarding a record date for the issuance of the Contingent Value Rights ("CVRs") to stockholders of Kintara pursuant to the definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"). Kintara announced today that the CVRs will not be issued to stockholders of record of Kintara based on a record date of October 17, 2024, but rather will be issued stockholders of record of Kint

      10/15/24 4:15:00 PM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KTRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Kintara Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $3.00 from $6.00 previously

      1/20/22 5:37:53 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aegis Capital reiterated coverage on Kintara Therapeutics with a new price target

      Aegis Capital reiterated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $5.00 from $7.00 previously

      9/30/21 9:44:25 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. initiated coverage on Kintara Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $6.00

      9/28/21 6:18:53 AM ET
      $KTRA
      Biotechnology: Pharmaceutical Preparations
      Health Care